NO20080495L - PEG-IFN-alfa og ribavirin for HBV-behandling - Google Patents

PEG-IFN-alfa og ribavirin for HBV-behandling

Info

Publication number
NO20080495L
NO20080495L NO20080495A NO20080495A NO20080495L NO 20080495 L NO20080495 L NO 20080495L NO 20080495 A NO20080495 A NO 20080495A NO 20080495 A NO20080495 A NO 20080495A NO 20080495 L NO20080495 L NO 20080495L
Authority
NO
Norway
Prior art keywords
ifn
peg
ribavirin
alpha
hbv treatment
Prior art date
Application number
NO20080495A
Other languages
English (en)
Inventor
Henricus Leonardus Antonius Janssen
Nigel Pluck
Matei Popescu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080495(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20080495L publication Critical patent/NO20080495L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer anvendelse av PEG-IFN-?-konjugater sammen med ribavirin for behandling av kroniske hepatitt B-infeksjoner. Foreliggende oppfinnelse tilveiebringer også en fremgangsmåte for behandling av kroniske hepatitt B-infeksjoner hos pasienter med behov for slik behandling, omfattende administrering av en mengde PEG-IFN-?-konjugat, sammen med en mengde ribavirin, som er effektiv for å behandle kronisk hepatitt B.
NO20080495A 2005-08-15 2008-01-28 PEG-IFN-alfa og ribavirin for HBV-behandling NO20080495L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107473 2005-08-15
PCT/EP2006/065026 WO2007020195A2 (en) 2005-08-15 2006-08-03 Peg-ifn alpha and ribavirin for hbv treatment

Publications (1)

Publication Number Publication Date
NO20080495L true NO20080495L (no) 2008-03-10

Family

ID=37654895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080495A NO20080495L (no) 2005-08-15 2008-01-28 PEG-IFN-alfa og ribavirin for HBV-behandling

Country Status (16)

Country Link
US (2) US20070071720A1 (no)
EP (1) EP1917037A2 (no)
JP (1) JP2009504706A (no)
KR (1) KR20080027944A (no)
CN (1) CN101242857A (no)
AR (1) AR057746A1 (no)
AU (1) AU2006281498A1 (no)
BR (1) BRPI0614863A2 (no)
CA (1) CA2617958A1 (no)
IL (1) IL188962A0 (no)
MX (1) MX2008002015A (no)
NO (1) NO20080495L (no)
RU (1) RU2008109649A (no)
TW (1) TW200740455A (no)
WO (1) WO2007020195A2 (no)
ZA (1) ZA200801248B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
WO2014027789A1 (ko) * 2012-08-13 2014-02-20 제이더블유크레아젠 주식회사 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질
TW201919653A (zh) * 2017-06-16 2019-06-01 加拿大商艾爾布圖斯生技公司 用於治療ｂ型肝炎之治療組合物及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
ATE307597T1 (de) * 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
WO2004024095A2 (en) * 2002-09-13 2004-03-25 Idenix (Cayman) Limited ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2006010256A1 (en) * 2004-07-26 2006-02-02 Transition Therapeutics Inc. Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
JP5089395B2 (ja) * 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
WO2006050421A1 (en) * 2004-11-02 2006-05-11 New River Pharmaceuticals Inc. Prodrugs of ribavirin with improved hepatic delivery
KR20080003933A (ko) * 2005-05-31 2008-01-08 노파르티스 아게 철이 발병에 관여하는 간질환의 치료

Also Published As

Publication number Publication date
IL188962A0 (en) 2008-08-07
JP2009504706A (ja) 2009-02-05
EP1917037A2 (en) 2008-05-07
AR057746A1 (es) 2007-12-12
US20080317714A1 (en) 2008-12-25
MX2008002015A (es) 2008-03-25
WO2007020195A3 (en) 2007-05-24
CA2617958A1 (en) 2007-02-22
TW200740455A (en) 2007-11-01
KR20080027944A (ko) 2008-03-28
CN101242857A (zh) 2008-08-13
ZA200801248B (en) 2008-11-26
US20070071720A1 (en) 2007-03-29
RU2008109649A (ru) 2009-09-27
AU2006281498A1 (en) 2007-02-22
BRPI0614863A2 (pt) 2011-04-19
WO2007020195A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
NO20072733L (no) Doseformer
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
WO2007111866A3 (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2008063727A3 (en) Combination therapy for treatment of viral infections
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
EA200401525A1 (ru) Способы лечения гепатита (варианты )
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
NO20080351L (no) Anvendelse av sanglifehrin i HCV
NO20054668L (no) Aplidin for multippelt myelom-behandling
NO20072285L (no) S-mirtazapin for behandling av hetetokter
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
ATE433459T1 (de) Desoxo-nonadepsipeptide
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
DK1663347T3 (da) Afereseindretning
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
MY166063A (en) Intravenous antiviral treatments
EA200700878A1 (ru) Лечение или предупреждение геморрагических вирусных инфекций с помощью иммуномодулирующих соединений
GB0220257D0 (en) Vaccine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application